PRGO:NYE-Perrigo Company plc (USD)

EQUITY | Drug Manufacturers - Specialty & Generic | New York Stock Exchange

Last Closing

USD 26.37

Change

-0.35 (-1.31)%

Market Cap

USD 12.59B

Volume

1.38M

Analyst Target

USD 57.88
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Perrigo Co PLC develops, manufactures and distributes over-the-counter and generic prescription pharmaceuticals, nutritional products and active pharmaceutical ingredients.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-12 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

+3.08 (+1.77%)

USD 79.77B
TAK Takeda Pharmaceutical Co Ltd A..

+0.02 (+0.15%)

USD 45.03B
HLN Haleon plc

-0.05 (-0.54%)

USD 43.99B
RDY Dr. Reddy’s Laboratories Ltd..

-0.21 (-1.42%)

USD 12.67B
CTLT Catalent Inc

-0.10 (-0.17%)

USD 10.78B
ELAN Elanco Animal Health

+0.07 (+0.50%)

USD 6.96B
BHC Bausch Health Companies Inc

-0.35 (-3.83%)

USD 3.37B
AMRX Amneal Pharmaceuticals, Inc. C..

-0.22 (-2.38%)

USD 2.80B
CPHI China Pharma Holdings Inc

N/A

USD 3.43M
YCBD cbdMD Inc

-0.05 (-9.04%)

USD 1.73M

ETFs Containing PRGO

FLWR:SW 15.27 % 0.00 %

N/A

N/A
ION Proshares S&P Global Core.. 3.96 % 0.00 %

+0.10 (+-0.29%)

USD 2.90M
M7ES:XETRA HANetf ICAV - Sprott Ener.. 3.37 % 0.00 %

+0.03 (+-0.29%)

USD 4.70M
UDIV:XETRA Global X SuperDividend UC.. 1.25 % 0.00 %

+0.01 (+-0.29%)

USD 3.03M
SDIV:SW Global X SuperDividend UC.. 1.25 % 0.00 %

-0.02 (-0.29%)

USD 0.17B
GNRX 0.00 % 0.55 %

N/A

N/A
PILL Direxion Daily Pharmaceut.. 0.00 % 0.98 %

-0.27 (-0.29%)

N/A
XPH SPDR® S&P Pharmaceutical.. 0.00 % 0.35 %

-0.32 (-0.29%)

N/A
ISRL:LSE 0.00 % 0.00 %

N/A

N/A
TASE:LSE 0.00 % 0.00 %

N/A

N/A
QDVM:F 0.00 % 0.00 %

N/A

N/A
QDVM:XETRA 0.00 % 0.00 %

N/A

N/A
WSRD:CA Wealthsimple Developed Ma.. 0.00 % 0.00 %

-0.08 (-0.29%)

CAD 0.71B
FLWG:LSE 0.00 % 0.00 %

N/A

N/A
FLWR:LSE 0.00 % 0.00 %

N/A

N/A
BLUM:XETRA 0.00 % 0.00 %

N/A

N/A
HLIT:CA Global X Lithium Producer.. 0.00 % 0.00 %

+0.20 (+-0.29%)

CAD 0.01B
BLUM:F 0.00 % 0.00 %

N/A

N/A
SDIP:LSE Global X SuperDividend UC.. 0.00 % 0.00 %

+0.01 (+-0.29%)

USD 0.19B
SDIU:LSE Global X SuperDividend UC.. 0.00 % 0.00 %

-0.09 (-0.29%)

USD 0.61M

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -18.05% 7% C- 10% F
Dividend Return 2.57% 50% F 45% F
Total Return -15.48% 7% C- 11% F
Trailing 12 Months  
Capital Gain -8.72% 7% C- 12% F
Dividend Return 3.81% 50% F 50% F
Total Return -4.91% 7% C- 13% F
Trailing 5 Years  
Capital Gain -45.11% 29% F 10% F
Dividend Return 10.47% 40% F 31% F
Total Return -34.64% 36% F 10% F
Average Annual (5 Year Horizon)  
Capital Gain -12.95% 13% F 4% F
Dividend Return -10.62% 13% F 5% F
Total Return 2.33% 80% B- 54% F
Risk Return Profile  
Volatility (Standard Deviation) 8.14% 100% F 84% B
Risk Adjusted Return -130.37% 7% C- N/A F
Market Capitalization 12.59B N/A N/A N/A N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio N/A N/A N/A
Price / Cash Flow Ratio N/A N/A N/A
Price/Free Cash Flow Ratio N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A
Return on Invested Capital N/A N/A N/A
Return on Assets N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector